Last Thursday the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) officially announced it was designating cannabidiol (CBD) – a non-psychoactive cannabis compound – as a medicine that can be administered for the purpose of “restoring, correcting, or modifying physiological functions.” This means that CBD products, which British law has been silent on until […]